COMP <GO>
GHM vs MLAB // EV/EBITDA & P/E VALUATION
Graham Corporation (NYSE) VS. Mesa Laboratories Inc. (NASDAQ) • 15-METRIC TALLY: GHM 7
— MLAB 6
▲ EV/EBITDA & P/E VALUATION LEADER: GHM
LAST: $71.69 (+0.75%) • MKT CAP: $841.4M
valuation
28.6x
LAST: $133.03 (+1.30%) • MKT CAP: $744.4M
valuation
33.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GHM VS. MLAB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GHM | MLAB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.50% | 63.50% | -40.00 | MLAB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.90% | 9.30% | +1.60 | GHM | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 28.6x | 33.6x | -5.00 | GHM | /valuation <GO> |
| Free Cash Flow Yield | -0.01% | 5.32% | -5.33 | MLAB | /fcf-yield <GO> |
| Operating Margin | 6.10% | 7.40% | -1.30 | MLAB | /operating-margins <GO> |
| Net Profit Margin | 5.10% | 2.70% | +2.40 | GHM | /net-margins <GO> |
| Revenue Growth (YoY) | 16.90% | 3.40% | +13.50 | GHM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.47% | -0.47 | MLAB | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.67 | 2.07 | +2.60 | GHM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MLAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.9 | 49.0 | -12.06 | MLAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 56.5x | 103.1x | -46.60 | GHM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $841.4M | $744.4M | $97.0M | GHM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GHM REV | MLAB REV | GHM GROSS % | MLAB GROSS % | GHM FCF | MLAB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $245.3M | $249.1M | 23.5% | 63.5% | -$121.0K | $39.6M |
| FY 2024 | $209.9M | $241.0M | 25.2% | 62.6% | $5.4M | $42.6M |
| FY 2023 | $185.5M | $216.2M | — | — | $28.1M | $44.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GHM // BETA —
MLAB // BETA —